Log in | Register

Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis

D. Cook| Y. Arabi| N. D. Ferguson| D. Heels-Ansdell| A. Freitag| E. McDonald| F. Clarke| S. Keenan| G. Pagliarello| W. Plaxton| M. Herridge| T. Karachi| S. Vallance| J. Cade| T. Crozier| S. Alves da Silva| R. Costa Filho| N. Brandao| I. Watpool| T. McArdle| G. Hollinger| Y. Mandourah| M. Al-Hazmi| N. Zytaruk| N. K. J. Adhikari
Original Article
Volume 39, Issue 12 / December , 2013

Pages 2115 - 2125

Abstract

Purpose

To analyze the frequency, rationale and determinants of attending physicians requesting that their eligible patients not be approached for participation in a thromboprophylaxis trial.

Methods

Research personnel in 67 centers prospectively documented eligible non-randomized patients due to physicians declining to allow their patients to be approached.

Results

In 67 centers, 3,764 patients were enrolled, but 1,460 eligible patients had no consent encounter. For 218 (14.9 %) of these, attending physicians requested that their patients not be approached. The most common reasons included a high risk of bleeding (31.2 %) related to fear of heparin bioaccumulation in renal failure, the presence of an epidural catheter, peri-operative status or other factors; specific preferences for thromboprophylaxis (12.4 %); morbid obesity (9.6 %); uncertain prognosis (6.4 %); general discomfort with research (3.7 %) and unclear reasons (17.0 %). Physicians were more likely to decline when approached by less experienced research personnel; considering those with >10 years of experience as the reference category, the odds ratios (OR) for physician refusals to personnel without trial experience was 10.47 [95 % confidence interval (CI) 2.19–50.02] and those with less than 10 years experience was 1.72 (95 % CI 0.61–4.84). Physicians in open rather than closed units were more likely to decline (OR 4.26; 95 % CI 1.27–14.34). Refusals decreased each year of enrollment compared to the pilot phase.

Conclusions

Tracking, analyzing, interpreting and reporting the rates and reasons for physicians declining to allow their patients to be approached for enrollment provides insights into clinicians’ concerns and attitudes to trials. This information can encourage physician communication and education, and potentially enhance efficient recruitment.

Keywords

References

  1. Taylor KM, Margolese RG, Soskolne CL (1984) Physicians’ reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310:1363–1367
    • View reference on PubMed
    • View reference on publisher's website
  2. Ellis PM, Butow PN, Simes RJ et al (1999) Barriers to participation in randomised clinical trials for early breast cancer among Australian cancer specialists. Aust N Z J Surg 69:505–510
    • View reference on publisher's website
  3. Rahman M, Morita S, Fukui T, Sakamoto J (2004) Physicians’ reasons for not entering their patients in a randomized controlled trial in Japan. Tohoku J Exp Med 203:104–109
    • View reference on publisher's website
  4. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, Troché G, Ricard JD, Nitenberg G, Papazian L, Azoulay E, Bellissant E, The CATS Study Group (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684
    • View reference on PubMed
    • View reference on publisher's website
  5. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAPII Investigators (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362(9):779–789. doi:10.1056/NEJMoa0907118
    • View reference on PubMed
    • View reference on publisher's website
  6. Clarke F, Zytaruk N, Fowler R, Heels-Ansdell D, Crowther M, Freitag A, Karachi T, Pagliarello G, Cade J, Bellomo R, Keenan S, Reynolds S, Wood G, Paunovic B, Plaxton W, Hollinger G, Chittock D, Poirier G, Lopes R, Mandourah Y, Shaikh N, Al-Hazmi M, Al-Azem A, Ostermann M, Brandao N, Costa Filho R, Alves da Silva S, Teixeira C, Rocha M, Guimaraes H, Cook D (2012) Physicians declining patient enrolment into clinical trials: incidence and insights. Am J Resp Crit Care Med 185:A2543 (abstract)
  7. Cook D, Meade M, Guyatt G et al (2011) PROphylaxis for ThromboEmbolism in Critical care Trial protocol and analysis plan. J Crit Care 26:223.e1–223.e9
    • View reference on publisher's website
  8. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314
    • View reference on publisher's website
  9. Cook DJ, Rocker G, Meade M et al (2005) PROphylaxis for ThromboEmbolism in Critical care Trial (PROTECT): a pilot study. J Crit Care 20:364–372
    • View reference on PubMed
    • View reference on publisher's website
  10. Douketis J, Cook DJ, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hebert PC, Pagliarello G, Marshall JC, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther MA, Canadian Critical Care Trials Group (2008) Renal insufficiency with the low-molecular-weight heparin dalteparin: An assessment of safety and pharmacodynamics. The DIRECT (Dalteparin’s Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 168(16):1805–1812
    • View reference on PubMed
    • View reference on publisher's website
  11. Austin PC, Goel V, Van Walraven C (2001) An introduction to multilevel regression models. Can J Public Health 92(2):150
    • View reference on PubMed
  12. Mehta S, Burry LD, Cook DJ, Fergusson DA, Steinberg M, Granton JT, Herridge MS, Ferguson ND, Devlin JW, Tanios MA, Dodek PE, Fowler RA, Burns KE, Jacka MJ, Olafson K, Skrobik Y, Hebert PC, Sabri H, Meade MO, SLEAP Investigators and the Canadian Critical Care Trials Group (2012) A randomized trial of daily sedative interruption in mechanically ventilated critically ill patients cared for with a sedation protocol. JAMA. doi:10.1001/jama.2012.1387
  13. Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, Zhou Q, Matte A, Walter S, Lamontagne F, Granton JT, Arabi Y, Arroliga A, Stewart TE, Slutsky AS, Meade MO (2013) OSCILLATE Trial Investigators and the Canadian Critical Care Trials Group. N Engl J Med 368(9):798–805
    • View reference on publisher's website
  14. The RENAL Replacement Therapy Trial Investigators (2009) Screening and study enrolment in the randomized evaluation of normal vs. augmented level (RENAL) replacement therapy trial. Blood Purif 27:199–205
    • View reference on publisher's website
  15. Cook DJ, McMullin J, Hodder R, Heule M, Pinilla J, Dodek P, Stewart T, Canadian ICU Directors Group (2001) Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care 5(6):336–342
    • View reference on PubMed
    • View reference on publisher's website
  16. Cooper DJ, Bishop N, Cade J, Finfer S, Gallus A, Myburgh J, Australian and New Zealand Intensive Care Society Clinical Trials Group (2005) Thromboprophylaxis for intensive care patients in Australia and New Zealand: a brief survey report. J Crit Care 20(4):354–356
    • View reference on PubMed
    • View reference on publisher's website
  17. Cook DJ, Meade MO, Guyatt GH, Griffith LE, Granton J, Geerts W, Crowther M, Canadian Critical Care Trials Group (2004) Clinically important deep vein thrombosis in the ICU: a survey of intensivists. Crit Care 8:R145–R152
    • View reference on PubMed
    • View reference on publisher's website
  18. Lacherade JC, Cook DJ, Heyland D, Chrusch C, Brochard L, Brun-Buisson C, French and Canadian ICU Directors Groups (2003) Prevention of venous thromboembolism (VTE) in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 18(4):228–237
    • View reference on PubMed
    • View reference on publisher's website
  19. Cook DJ, Laporta D, Skrobik Y, Peters S, Sharpe M, Murphy P, Chin D, Crowther M, Canadian ICU Directors Group (2001) Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study. J Crit Care 16(4):161–166
    • View reference on PubMed
    • View reference on publisher's website
  20. Patel R, Cook DJ, Meade MO, Griffith L, Mehta S, Rocker G, Marshall J, Hodder R, Martin C, Heyland D, Peters S, Muscedere J, Soth M, Campbell N, Guyatt GH, Canadian Critical Care Trials Group (2005) Burden of illness: thrombo-embolism in critical care (BITEC) study. J Crit Care 20:341–347
    • View reference on PubMed
    • View reference on publisher's website
  21. Cook DJ, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt GH (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 33(7):1565–1571
    • View reference on PubMed
    • View reference on publisher's website
  22. Cook DJ, Douketis J, Meade M, Guyatt G, Zytaruk N, Granton J, Skrobik Y, Albert M, Fowler R, Hebert P, Pagliarello G, Friedrich J, Freitag A, Karachi T, Rabbat C, Heels-Ansdell D, Geerts W, Crowther M, Canadian Critical Care Trials Group (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency: prevalence, incidence and risk factors. Crit Care 12(2):R32-1–R32-9
    • View reference on publisher's website
  23. Lauzier F, Arnold D, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates J, Karachi T, Lopes R, Zytaruk N, Finfer S, Crowther M, Cook D For the PROTECT Investigators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2013) Risk factors and consequences of major bleeding in medical-surgical critically Ill patients: a cohort study. Intensive Care Med (in press).
  24. Zarychanski R, Lim W, Rocha M, McIntyre L, Lamontagne F, Dodek P, Pai M, Cooper DJ, Alhashemi J, Zytaruk N (2011) Do statins influence DVT risk in critically ill patients? Crit Care Med 39(12 :suppl):A112
  25. Zytaruk N, Meade M, Mehta S, Hall R, Granton J, Ferguson ND, Freitag A, Muscedere J, Fowler R, Skrobik Y, Jacka M, Marshall J, Lauzier F, Lamontagne F, Turgeon A, Vlahakis N, Klinger J, Devereaux PJ, Ostermann M, Berwanger O, Khwaja K, Burry L, Freidrich J, Burns KEA, Herridge M, Cooper DJ, Bersten A, Heels-Ansdell D, Cook DJ, PROTECT Investigators, the CCCTG and the ANZICS-CTG (2012) Risk factors for pulmonary embolism in medical-surgical ICU patients. Am J Resp Crit Care Med 185:A2359
  26. Zarychanski R, Lauzier F, Turgeon A, Marshall J, Nates J, Cox M, Arabi Y, Qushmaq I, Zytaruk N, Cook DJ (2011) VTE risk factors in medical-surgical ICU patients. Crit Care Med 39(12 suppl):A672
  27. Segelov E, Tattersall MHN, Coates AS (1992) Redressing the balance: ethics of not entering an eligible patient on a randomized clinical trial. Ann Oncol 3:103–105
    • View reference on PubMed
    • View reference on publisher's website
  28. Vist GE, Hagen KB, Devereaux PJ, Bryant D, Kristoffersen DT, Oxman AD (2005) Systematic review to determine whether participation in a trial influences outcome. BMJ 330:1175–1182
    • View reference on PubMed
    • View reference on publisher's website
  29. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescot R (1999) Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52(12):1143–1156
    • View reference on PubMed
    • View reference on publisher's website
  30. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K (2009) A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 180(10):E47–E57
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement